- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Type 2 Inflammatory Diseases and Impact on Quality of Life
Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.
EP: 1.Navigating the Challenges of Respiratory Diseases
EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis
EP: 3.Linking Type 2 Inflammation to Asthma and COPD
EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases
EP: 5.Type 2 Inflammation: The Link Between AD and PN
EP: 6.Personalizing Treatment Selection
EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions
EP: 8.Role of Biologics in Dermatological Care
EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation
EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases
EP: 11.Addressing Unmet Needs and Emerging Agents
EP: 12.Future Directions for Type 2 Inflammation Management
EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life
EP: 14.Type 2 Inflammation Biomarkers
EP: 15.How Type 2 Inflammation Influences Treatment Choices
EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities
EP: 17.Patient Education and Emerging Therapies
EP: 18.Unmet Needs and Future Research
- How do type 2 inflammatory diseases, such as asthma, eosinophilic esophagitis, or chronic rhinosinusitis with nasal polyps, impact patients’ quality of life?
- What challenges do patients face in managing their type 2 inflammatory disease(s) on a daily basis?
- Describe type 2 inflammation. What diseases beyond those mentioned above can it be associated with?
- What causes this overactive inflammatory response? In your clinical practice, how often do you see patients with type 2 inflammation?
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
